Frequency, risk factors, and outcomes of central nervous system relapse in lymphoma patients treated with dose‐adjusted EPOCH plus rituximab

Overview of attention for article published in American Journal of Hematology, August 2017

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
Good Attention Score compared to outputs of the same age (79th percentile)
Good Attention Score compared to outputs of the same age and source (71st percentile)

Mentioned by

twitter: 16 X users

Readers on

mendeley: 29 Mendeley

So far, Altmetric has seen 19 X posts from 16 X users, with an upper bound of 66,817 followers.

RT @chadinabhan: Our data on CNS relapse in #NHL pts treated w EPOCH-R. Incidence appears similar; collaboration w @adampetrich & al. https…

Our data on CNS relapse in #NHL pts treated w EPOCH-R. Incidence appears similar; collaboration w @adampetrich & al. https://t.co/kA9recDUkT

RT @chanyooncheah: 6% CNS relapse risk among pts w aggressive lymphoma treated with da-EPOCH-R #lymsm https://t.co/cBdLeNYmyJ

This page shows the most recent X posts that mention this research output. Click here to find out how to access more activity, including 15 additional X posts.